CQP 201-403 in Parkinson's disease: an open-label pilot study.
The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over an average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in sufficient frequency in this group of patients to be accurately assessed. The most serious adverse effect encountered was prolonged confusion with psychosis. This study suggests that CQP 201-403 may be of value in the treatment of Parkinson's disease.
Pfeiffer
R F
RF
Section of Neurology, University of Nebraska Medical Center, Omaha 68105-1065.
Herrera
L H
LH
Glaeske
C S
CS
Hofman
R E
RE
D000368:Aged; D015259:Dopamine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010865:Pilot Projects
D015259:Dopamine Agents; D004873:Ergolines; C049850:CQP 201-403